Last updated: February 19, 2026
This analysis examines the market landscape and projects pricing trends for the drug identified by National Drug Code (NDC) 69339-0162. The drug, a fixed-dose combination of hydrochlorothiazide and triamterene, is indicated for the management of hypertension. Market forces, including patent status, generic competition, and prescribing patterns, will influence its future price trajectory.
What is NDC 69339-0162?
NDC 69339-0162 corresponds to hydrochlorothiazide 25 mg / triamterene 37.5 mg, an oral diuretic medication. It is prescribed to treat high blood pressure. The drug functions by helping the body eliminate excess salt and water.
Key Components and Mechanism of Action
Hydrochlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule. Triamterene is a potassium-sparing diuretic that acts on the collecting duct, reducing sodium reabsorption and potassium excretion. Their combination offers a synergistic effect in managing hypertension while mitigating excessive potassium loss.
Approved Indications and Formulations
The primary indication for hydrochlorothiazide 25 mg / triamterene 37.5 mg is the treatment of hypertension. It is available in oral capsule form. The specific formulation under NDC 69339-0162 is manufactured by Amneal Pharmaceuticals LLC. [1]
Patent Landscape and Market Exclusivity
The patent status of a drug is a critical determinant of its market exclusivity and subsequent pricing power. For generic drugs, patent expiration opens the door for increased competition, typically leading to price erosion.
Original Patent Expiration and Generic Entry
The original innovator drug for hydrochlorothiazide and triamterene combination therapy, Dyazide, manufactured by SmithKline Beecham (now GlaxoSmithKline), saw its primary patents expire in the late 1990s and early 2000s. This allowed for the introduction of generic versions. [2]
Current Patent Status for NDC 69339-0162
As NDC 69339-0162 represents a generic formulation, its primary market exclusivity would have been tied to the expiration of patents covering the active pharmaceutical ingredients (APIs) and their methods of use and formulation. Specific patents for this generic product itself are generally not subject to the same long-term exclusivity as innovator drugs. The focus shifts to manufacturing process patents and any remaining formulation patents.
Competitive Market Dynamics
The presence of multiple manufacturers producing generic versions of hydrochlorothiazide and triamterene impacts pricing through supply and demand dynamics.
Number of Generic Manufacturers
The market for hydrochlorothiazide/triamterene has been competitive for years, with numerous generic manufacturers offering the product. Notable manufacturers include Teva Pharmaceuticals, Aurobindo Pharma, Mylan, and Amneal Pharmaceuticals. [3] The ability of Amneal Pharmaceuticals to produce this specific NDC code indicates its established presence in the generic market.
Market Share and Pricing Pressure
With a fragmented generic market, pricing is highly sensitive to competition. Manufacturers compete on cost of production, distribution networks, and formulary placement. The average wholesale price (AWP) for hydrochlorothiazide/triamterene 25/37.5 mg capsules has shown a general downward trend over the past decade due to sustained generic competition. [4]
Prescription Trends and Demand Analysis
Understanding how physicians prescribe this medication and patient demand provides insight into its market relevance.
Prescribing Patterns for Diuretics
Hydrochlorothiazide/triamterene remains a commonly prescribed medication for hypertension, particularly in primary care settings. Its efficacy, affordability, and established safety profile contribute to its continued use. However, newer antihypertensive agents with potentially better cardiovascular outcomes and fewer side effects are also gaining traction, which could influence long-term demand.
Utilization Data
According to IQVIA data, the hydrochlorothiazide/triamterene combination therapy class sees substantial prescription volume annually. While precise figures for NDC 69339-0162 are proprietary, the overall market for this drug class suggests consistent demand. [5]
Price Projections and Influencing Factors
Future pricing for NDC 69339-0162 will be shaped by a confluence of market forces.
Impact of Generic Competition
Continued generic competition is expected to maintain downward pressure on prices. As new generic manufacturers enter the market or existing ones optimize production, further price decreases are probable. The average selling price (ASP) for the 25mg/37.5mg formulation has seen an average annual decline of approximately 5-7% over the past five years. [4]
Manufacturing Costs and Raw Material Prices
Fluctuations in the cost of APIs (hydrochlorothiazide and triamterene) and other manufacturing inputs can influence wholesale prices. Increases in raw material costs could lead to modest price adjustments, but these are likely to be absorbed by manufacturers to remain competitive.
Payer Policies and Formulary Status
Payer policies, including preferred drug lists and co-payment structures, significantly affect out-of-pocket costs for patients and market access for manufacturers. Generic drugs like hydrochlorothiazide/triamterene are typically placed on preferred drug tiers by most insurers due to their cost-effectiveness, ensuring broad access. [6]
Alternative Therapies
The development and adoption of newer antihypertensive classes, such as ARNI (angiotensin receptor-neprilysin inhibitors) or novel combination therapies, could gradually reduce the market share of older, established diuretics. This shift, if it accelerates, could impact the demand and, consequently, the pricing of hydrochlorothiazide/triamterene over the long term.
Price Projections
Short-term (1-2 years): Expect a continued gradual decline in wholesale prices, likely in the range of 3-6% annually, driven by intense generic competition.
Medium-term (3-5 years): The rate of price decline may stabilize or slow to 2-4% annually. Demand will remain steady, but the impact of newer therapies could begin to moderate growth.
Long-term (5+ years): Pricing will be heavily influenced by the continued adoption of novel treatments and the generic lifecycle. If generic competition remains robust, prices may continue to decline, albeit at a slower pace. Price erosion beyond 5-7 years could approach levels where some manufacturers may re-evaluate production if margins become unsustainably thin.
Key Takeaways
- NDC 69339-0162 is a generic formulation of hydrochlorothiazide 25 mg / triamterene 37.5 mg, a widely used antihypertensive medication.
- The drug benefits from a patent-expired status, allowing for robust generic competition.
- The market is characterized by multiple generic manufacturers, leading to consistent price pressure.
- Prescription volumes remain substantial due to the drug's efficacy, affordability, and established safety profile.
- Price projections indicate a continued gradual decline in the short to medium term, with potential stabilization in the long term, contingent on market dynamics and the introduction of novel therapies.
Frequently Asked Questions
What is the typical wholesale acquisition cost (WAC) for NDC 69339-0162?
The WAC for NDC 69339-0162 varies by distributor and volume but generally falls within the range of $0.08 to $0.25 per capsule for bulk purchases. [4]
Are there any pending patent challenges or exclusivities that could affect the market for this NDC?
As a generic product with long-standing patent expirations for its APIs, significant new patent challenges directly impacting its market exclusivity are unlikely. The focus would be on manufacturing process patents.
How does the price of NDC 69339-0162 compare to other generic diuretics?
Hydrochlorothiazide/triamterene 25/37.5 mg is competitively priced compared to other fixed-dose diuretic combinations, often falling within a similar cost bracket based on dosage and API combinations.
What are the primary drivers of price fluctuations for generic drugs like this one?
Price fluctuations are primarily driven by the number of generic competitors in the market, manufacturing efficiency, raw material costs, and payer reimbursement policies.
What is the expected impact of biosimilar competition on this drug's market?
This drug is a small molecule generic, not a biologic, therefore biosimilar competition is not applicable. The relevant competitive landscape is solely generic.
Citations
[1] U.S. Food & Drug Administration. (n.d.). National Drug Code Directory. Retrieved from https://www.fda.gov/drugs/national-drug-code-directory
[2] GlaxoSmithKline. (2000). Annual Report. (Specific patent details are often proprietary and not publicly disclosed in general annual reports; historical market analysis data from industry databases confirm patent expiry periods for Dyazide).
[3] IQVIA. (2023). MIDAS™ Data. (Proprietary market data on pharmaceutical manufacturers and product portfolios. Specific manufacturer lists are available via subscription services).
[4] First Databank, Inc. (2023). First Choices Drug Pricing Database. (Proprietary database providing drug pricing information including AWP and ASP).
[5] IQVIA. (2023). MIDAS™ Data. (Proprietary market data on pharmaceutical prescription volumes and market share analysis).
[6] Centers for Medicare & Medicaid Services. (2023). Medicare Part D Prescription Drug Plans. Retrieved from https://www.medicare.gov/plan-compare/ (General information on formulary tiering and coverage policies).
